Ann-Muriel Steff received her degree in Pharmacy and PhD in Biochemistry and Cellular Biology from Université de Montpellier, in France. She completed post-doctoral studies in Immunology at Institut de Recherches Cliniques de Montréal, Canada. After her post-doc, Ann-Muriel worked in various research and project leadership roles in a variety of life sciences organizations (biotechnology, the World Anti-Doping Agency (WADA), and Charles River Laboratories in Canada). In 2011, she joined GSK Vaccines as Expert Scientist in Preclinical Immunology and had positions of increasing responsibilities as Project Leader in vaccine Discovery/Technology. She was Head of Preclinical R&D for the GSK Vaccines US site until December 2022. Ann-Muriel joined CEPI in early 2023, as Project Leader for Disease X vaccine library development.